Frazier Healthcare Partners has raised $1.3 billion for a new early-stage investment fund targeting innovative biotech companies. The fund will fuel advancements in discovery and clinical development phases, focusing on transformative therapeutics and cutting-edge modalities. This commitment reflects growing investor confidence amid a challenging market, aiming to support next-generation healthcare breakthroughs and accelerate the translation of novel science into impactful treatments.